CD4 and chronic kidney disease: Clinically, the substantial increases in CX3CR1+/CD4+ T‐cells observed here are of particular note since inhibition of CX3CR1 to ameliorate atherosclerosis progression is promising,82, 83 as is CX3CR1 modulation in the treatment of CKD.84